Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7963380 | 0.78 | GAA (0.53) | LMNAMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8120185 | 0.76 | LMNA (0.70) | HRH3LMNACYP1A2ALOX15SIGMAR1 | |
| SCHEMBL2877981 | 0.75 | L3MBTL1 (0.72) | HRH3L3MBTL1CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL3904815 | 0.74 | L3MBTL1 (0.76) | HRH3L3MBTL1LMNACYP1A2MAPK1 | |
| SCHEMBL5507736 | 0.74 | L3MBTL1 (0.69) | HRH3L3MBTL1CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL10624598 | 0.74 | L3MBTL1 (0.69) | HRH3L3MBTL1CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL5500455 | 0.74 | L3MBTL1 (0.69) | HRH3L3MBTL1CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL30701387 | 0.74 | L3MBTL1 (0.69) | HRH3L3MBTL1CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL1258997 | 0.73 | L3MBTL1 (0.45) | L3MBTL1LMNACYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL3926676 | 0.73 | L3MBTL1 (0.75) | HRH3L3MBTL1LMNACYP1A2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005110406-A2 | PHENYL DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256177-A1 | Phenyl derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256177-A1 | Phenyl derivatives for the treatment of abnormal cell growth | CCND3, CDC25C, CCNA1 | HRH3 869/4885L3MBTL1 559/4885LMNA 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.